These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

764 related items for PubMed ID: 28154373

  • 1. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
    Ferguson GT, Karpel J, Bennett N, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.
    NPJ Prim Care Respir Med; 2017 Feb 02; 27(1):7. PubMed ID: 28154373
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age.
    Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2016 Feb 02; 11():2701-2710. PubMed ID: 27843306
    [Abstract] [Full Text] [Related]

  • 3. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies.
    Buhl R, Singh D, de la Hoz A, Xue W, Ferguson GT.
    Adv Ther; 2020 Aug 02; 37(8):3485-3499. PubMed ID: 32462607
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
    Buhl R, de la Hoz A, Xue W, Singh D, Ferguson GT.
    Adv Ther; 2020 Oct 02; 37(10):4175-4189. PubMed ID: 32671684
    [Abstract] [Full Text] [Related]

  • 5. Effects of baseline symptom burden on treatment response in COPD.
    Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, Singh D.
    Int J Chron Obstruct Pulmon Dis; 2019 Oct 02; 14():181-194. PubMed ID: 30655665
    [Abstract] [Full Text] [Related]

  • 6. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials.
    Rabe KF, Chalmers JD, Miravitlles M, Kocks JWH, Tsiligianni I, de la Hoz A, Xue W, Singh D, Ferguson GT, Wedzicha J.
    Adv Ther; 2021 Jan 02; 38(1):579-593. PubMed ID: 33175291
    [Abstract] [Full Text] [Related]

  • 7. [The efficacy and safety of tiotropium/olodaterol fixed-dose combination in Chinese patients with chronic obstructive pulmonary disease: a pooled subgroup analysis of TONADO 1+2].
    Bai CX, Tang Y, Xin JB, Li YL, Li ZK, Kang J, Huang JA, Xiao W, Wen ZG, Fu XH, He B, Liu CT, Chen P.
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Nov 12; 42(11):838-844. PubMed ID: 31694094
    [Abstract] [Full Text] [Related]

  • 8. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
    Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N, Abrahams R, Schmidt O, Bjermer L.
    Respir Med; 2015 Oct 12; 109(10):1312-9. PubMed ID: 26320402
    [Abstract] [Full Text] [Related]

  • 9. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
    Singh D, Gaga M, Schmidt O, Bjermer L, Grönke L, Voß F, Ferguson GT.
    Respir Res; 2016 Jun 18; 17(1):73. PubMed ID: 27316465
    [Abstract] [Full Text] [Related]

  • 10. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, Fukuchi Y.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun 18; 11():2017-27. PubMed ID: 27621608
    [Abstract] [Full Text] [Related]

  • 11. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Mölken M, Goosens LM, Buyukkaramikli N, Acciai V.
    Ther Adv Respir Dis; 2016 Oct 18; 10(5):391-401. PubMed ID: 27405723
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R.
    Int J Chron Obstruct Pulmon Dis; 2014 Oct 18; 9():1133-44. PubMed ID: 25342898
    [Abstract] [Full Text] [Related]

  • 13. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.
    Pulm Pharmacol Ther; 2015 Jun 18; 32():53-9. PubMed ID: 25956072
    [Abstract] [Full Text] [Related]

  • 14. COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy.
    Calverley PMA, Hoz A, Xue W, Ferguson GT, Miravitlles M.
    COPD; 2020 Oct 18; 17(5):477-484. PubMed ID: 32928003
    [Abstract] [Full Text] [Related]

  • 15. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA, Cates CJ.
    Cochrane Database Syst Rev; 2015 Oct 22; (10):CD008989. PubMed ID: 26490945
    [Abstract] [Full Text] [Related]

  • 16. Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.
    Bai C, Ichinose M, Lee SH, Lee KH, Jöns O, Bothner U, Zhao Y, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2017 Oct 22; 12():3329-3339. PubMed ID: 29200840
    [Abstract] [Full Text] [Related]

  • 17. Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.
    LaForce C, Derom E, Bothner U, Kloer IM, Trampisch M, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct 22; 13():1819-1831. PubMed ID: 29910611
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT, Fležar M, Korn S, Korducki L, Grönke L, Abrahams R, Buhl R.
    Adv Ther; 2015 Jun 22; 32(6):523-36. PubMed ID: 26112656
    [Abstract] [Full Text] [Related]

  • 19. Study Design of VESUTO®: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease.
    Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T, Takizawa A, Grönke L, Hirata K.
    Adv Ther; 2017 Jul 22; 34(7):1622-1635. PubMed ID: 28537001
    [Abstract] [Full Text] [Related]

  • 20. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T.
    Int J Chron Obstruct Pulmon Dis; 2016 Jul 22; 11():891-8. PubMed ID: 27217742
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.